IRONWOOD PHARMACEUTICALS, INC. (IRWD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 32.85M USD | Liabilities, Current |
| Cash and equivalents | 79.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 112.73M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $32.85M | $79.13M | (m) | $112.73M | (m) | (m) |
| 2026-03-31 | (m) | $236.31M | $220.47M | (m) | $105.84M | (m) | (m) |
| 2025-12-31 | (m) | $242.22M | $215.46M | (m) | $46.74M | (m) | (m) |
| 2025-09-30 | (m) | $242.50M | $140.41M | (m) | $120.37M | (m) | (m) |
| 2025-06-30 | (m) | $232.53M | $92.85M | (m) | $86.17M | (m) | (m) |
| 2025-03-31 | (m) | $48.10M | $108.48M | (m) | $39.77M | (m) | (m) |
| 2024-12-31 | (m) | $38.85M | $88.56M | (m) | $81.89M | (m) | (m) |
| 2024-09-30 | (m) | $49.38M | $88.21M | (m) | $76.20M | (m) | (m) |
| 2024-06-30 | (m) | $45.51M | $105.52M | (m) | $58.11M | (m) | (m) |
| 2024-03-31 | (m) | $252.44M | $121.54M | (m) | $72.02M | (m) | (m) |
| 2023-12-31 | (m) | $276.10M | $92.15M | (m) | $129.12M | (m) | (m) |
| 2023-09-30 | (m) | $280.58M | $110.16M | (m) | $124.55M | (m) | (m) |
| 2023-06-30 | (m) | $305.39M | $175.32M | (m) | $118.99M | (m) | (m) |
| 2023-03-31 | (m) | $23.84M | $740.34M | (m) | $115.75M | (m) | (m) |
| 2022-12-31 | (m) | $25.52M | $656.20M | (m) | $115.46M | (m) | (m) |
| 2022-09-30 | (m) | $27.12M | $574.19M | (m) | $116.55M | (m) | (m) |
| 2022-06-30 | (m) | $23.30M | $504.37M | (m) | $102.36M | (m) | (m) |
| 2022-03-31 | (m) | $147.40M | $593.37M | (m) | $105.52M | (m) | (m) |
| 2021-12-31 | (m) | $161.70M | $620.13M | (m) | $114.04M | (m) | (m) |
| 2021-09-30 | (m) | $145.69M | $574.28M | (m) | $101.77M | (m) | (m) |
| 2021-06-30 | (m) | $134.37M | $492.70M | (m) | $102.25M | (m) | (m) |
| 2021-03-31 | (m) | $23.60M | $438.47M | (m) | $87.15M | (m) | (m) |
| 2020-12-31 | (m) | $32.17M | $362.56M | (m) | $122.35M | (m) | (m) |
| 2020-09-30 | (m) | $32.90M | $307.56M | (m) | $113.25M | (m) | (m) |
| 2020-06-30 | (m) | $26.70M | $253.25M | (m) | $105.38M | (m) | (m) |
| 2020-03-31 | (m) | $27.59M | $231.14M | (m) | $17.70M | (m) | (m) |
| 2019-12-31 | (m) | $40.93M | $177.02M | (m) | $11.28M | $648.00K | (m) |
| 2019-09-30 | (m) | $52.80M | $139.23M | (m) | $2.02M | $2.30M | (m) |
| 2019-06-30 | (m) | $110.86M | $98.91M | (m) | $22.60M | $1.74M | (m) |
| 2019-03-31 | (m) | $118.57M | $119.05M | (m) | $3.29M | $593.00K | (m) |
| 2018-12-31 | (m) | $119.52M | $173.17M | (m) | $20.99M | (m) | (m) |
| 2018-09-30 | $171.59M | $112.58M | $141.56M | $19.84M | $10.19M | $76.00K | 1.52× |
| 2018-06-30 | $187.99M | $94.98M | $145.41M | $35.83M | $6.75M | $1.10M | 1.98× |
| 2018-03-31 | $199.44M | $62.34M | $144.79M | $49.66M | $4.99M | $1.71M | 3.20× |
| 2017-12-31 | $224.61M | $66.03M | $125.74M | $95.68M | $3.19M | $735.00K | 3.40× |
| 2017-09-30 | $229.70M | $64.49M | $162.64M | $62.78M | $4.28M | $479.00K | 3.56× |
| 2017-06-30 | $276.87M | $79.97M | $182.13M | $90.76M | $3.98M | (m) | 3.46× |
| 2017-03-31 | $296.49M | $78.89M | $133.32M | $162.02M | $1.15M | $1.51M | 3.76× |
| 2016-12-31 | $306.15M | $91.13M | $54.00M | $251.21M | $933.00K | $1.08M | 3.36× |
| 2016-09-30 | $321.05M | $95.31M | $182.94M | $136.94M | $1.17M | (m) | 3.37× |
| 2016-06-30 | $326.64M | $91.00M | $277.33M | $48.04M | $1.27M | (m) | 3.59× |
| 2016-03-31 | $435.36M | $78.11M | $280.93M | $153.53M | $908.00K | (m) | 5.57× |
| 2015-12-31 | $442.28M | $76.47M | $261.29M | $178.11M | $2.88M | (m) | 5.78× |
| 2015-09-30 | $464.88M | $67.78M | $248.08M | $214.23M | $2.57M | $0.00 | 6.86× |
| 2015-06-30 | $494.37M | $62.10M | $256.45M | $236.87M | $1.06M | $0.00 | 7.96× |
| 2015-03-31 | $216.73M | $59.81M | $63.69M | $152.17M | $862.00K | $4.95M | 3.62× |
| 2014-12-31 | $248.34M | $60.54M | $74.30M | $174.04M | $10.00K | $4.95M | 4.10× |
| 2014-09-30 | $265.34M | $54.06M | $51.27M | $213.69M | $380.00K | $13.04M | 4.91× |
| 2014-06-30 | (m) | $41.63M | $95.36M | $206.62M | (m) | $12.99M | (m) |
| 2014-03-31 | $332.28M | $38.50M | $205.13M | $127.14M | $13.00K | $23.41M | 8.63× |
| 2013-12-31 | $198.12M | $41.04M | $75.49M | $122.11M | $513.00K | $22.14M | 4.83× |
| 2013-09-30 | $242.51M | $39.70M | $144.45M | $97.94M | $125.00K | $20.56M | 6.11× |
| 2013-06-30 | (m) | $43.97M | $219.46M | $81.08M | (m) | $20.38M | (m) |
| 2013-03-31 | $242.04M | $62.68M | $105.30M | $136.73M | $12.00K | $19.70M | 3.86× |
| 2012-12-31 | $168.69M | $54.94M | $136.70M | $31.53M | $457.00K | $6.70M | 3.07× |
| 2012-09-30 | $193.49M | $35.58M | $125.87M | $67.46M | $169.00K | $965.00K | 5.44× |
| 2012-06-30 | $157.68M | $49.12M | $87.08M | $70.57M | $22.00K | (m) | 3.21× |
| 2012-03-31 | $202.22M | $52.28M | $131.61M | $70.50M | $109.00K | (m) | 3.87× |
| 2011-12-31 | $164.09M | $65.13M | $87.28M | $76.73M | $74.00K | (m) | 2.52× |
| 2011-09-30 | $175.20M | $70.85M | $68.82M | $106.31M | $74.00K | (m) | 2.47× |
| 2011-06-30 | $201.21M | $70.84M | $48.19M | $152.91M | $110.00K | (m) | 2.84× |
| 2011-03-31 | (m) | (m) | $46.21M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $248.05M | $64.43M | $44.32M | $203.71M | $19.00K | (m) | 3.85× |
| 2010-09-30 | (m) | (m) | $58.70M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $35.36M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $122.31M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $66.33M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |